©2024 Stanford Medicine
In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
Not Recruiting
Trial ID: NCT00788255
Purpose
Oxytocin is normally administered following delivery in pregnant patients to reduce
postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous
oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to
assess the coagulation changes of oxytocin in blood samples from pregnant patients using
thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic
properties of clot formation, and can provide rapid and detailed information about
coagulation changes. We aim to collect blood samples from pregnant patients to assess the
in-vitro effects of synthetic oxytocin on coagulation using TEG.
Official Title
In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
Stanford Investigator(s)
Alex Butwick
Professor of Anesthesiology, Perioperative and Pain Medicine (OB)
Lindsey Ralls
Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine
Eligibility
Inclusion Criteria:All obstetric patients with singleton pregnancies admitted to the labor
and delivery unit at Lucile Packard Childrens Hospital awaiting elective induction of labor
or elective Cesarean delivery. We will select 25 healthy ASA 1 patients with singleton
pregnancies who are scheduled for uncomplicated elective induction of labor. Gestational
age equal to or greater than 37 weeks.
Exclusion Criteria:Patients with underlying coagulation disorders. Patients with
thrombocytopenia. Patients with pregnancy-induced hypertension, pre-eclampsia. Patients
admitted for non-elective cesarean section. Patients in active labor. Patients requiring
the following medications prior to surgery: NSAIDS, aspirin, anticoagulants.
Patients with significant obstetric or medical disease. No patients <18 years of age will
be recruited.
Intervention(s):
drug: Final exogenous oxytocin concentration=22.5 μU/mL
drug: Final exogenous oxytocin concentration=30.1μU/mL
drug: Final exogenous oxytocin concentration=32.9μU/mL
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Alexander Butwick